Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Latest Information Update: 27 Dec 2023
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2023 Status changed from active, no longer recruiting to completed.
- 03 Nov 2023 Planned End Date changed from 9 Apr 2025 to 31 Oct 2024.
- 17 May 2021 Planned End Date changed from 31 Oct 2024 to 9 Apr 2025.